Reconnect Labs is a Swiss-precision drug development company recently out of stealth with three assets approaching Phase 2 trials in 2024. Their precision neuropsychiatry approach includes: AI-driven Psychological biomarkers, Precision Psychopharmacology and Novel MoAs.